AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 286: H2468-H2473, 2004. First published February 5, 2004; doi:10.1152/ajpheart.01207.2003
0363-6135/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/6/H2468    most recent
01207.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tawakol, A.
Right arrow Articles by Creager, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tawakol, A.
Right arrow Articles by Creager, M. A.

REPORT

Direct effect of ethanol on human vascular function

Ahmed Tawakol,1 Torbjørn Omland,3 and Mark A. Creager2

1Cardiac Unit, Department of Medicine, Massachusetts General Hospital, Boston 02114; 2Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115; and 3Department of Medicine, Akershus University Hospital, Nordbyhagen, Norway

Submitted 18 December 2003 ; accepted in final form 26 January 2004


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Epidemiological studies indicate that moderate ethanol consumption reduces cardiovascular mortality. Cellular and animal data suggest that ethanol confers beneficial effects on the vascular endothelium and increases the bioavailability of nitric oxide. The purpose of this study was to assess the effect of ethanol on endothelium-dependent, nitric oxide-mediated vasodilation in healthy human subjects. Forearm blood flow (FBF) was determined by venous occlusion plethysmography in healthy human subjects during intra-arterial infusions of either methacholine (0.3, 1.0, 3.0, and 10.0 mcg/min, n = 9), nitroprusside (0.3, 1.0, 3.0, and 10.0 mcg/min, n = 9), or verapamil (10, 30, 100, and 300 mcg/min, n = 8) before and during the concomitant intra-arterial infusions of ethanol (10% ethanol in 5% dextrose). Additionally, a time control experiment was conducted, during which the methacholine dose-response curve was measured twice during vehicle infusions (n = 5). During ethanol infusion, mean forearm and systemic alcohol levels were 227 ± 30 and 6 ± 0 mg/dl, respectively. Ethanol infusion alone reduced FBF (2.5 ± 0.1 to 1.9 ± 0.1 ml·dl–1·min–1, P < 0.05). Despite initial vasoconstriction, ethanol augmented the FBF dose-response curves to methacholine, nitroprusside, and verapamil (P < 0.01 by ANOVA for each). To determine whether this augmented FBF response was related to shear-stress-induced release of nitric oxide, FBF was measured during the coinfusion of ethanol and NG-nitro-L-arginine (l-NAME; n = 8) at rest and during verapamil-induced vasodilation. The addition of L-NAME did not block the ability of ethanol to augment verapamil-induced vasodilation. Ethanol has complex direct vascular effects, which include basal vasoconstriction as well as potentiation of both endothelium-dependent and -independent vasodilation. None of these effects appear to be mediated by an increase in nitric oxide bioavailability, thus disputing findings from preclinical models.

alcohol; nitric oxide; endothelial function; humans; verapamil; methacholine; nitruprusside; plethysmography

LARGE EPIDEMIOLOGICAL STUDIES demonstrate that moderate alcohol consumption is associated with a 40–60% reduction of mortality from coronary artery disease (10, 14, 16, 26, 35, 41). Several mechanisms may contribute to the decreased cardiovascular mortality, including favorable effects on lipoprotein metabolism such as increased HDL2 and HDL3 cholesterol subfractions (13, 43) and antithrombotic effects mediated by decreased platelet aggregation (37) and increased tissue plasminogen activator levels (20, 34). Furthermore, animal and cellular data suggest that ethanol confers beneficial effects on the vascular endothelium, increasing the bioavailability of nitric oxide (NO) (6, 8, 12, 15) and decreasing the synthesis of endothelin-1 (5).

In humans, ingestion of an alcoholic beverage acutely increases heart rate, cardiac output, and cardiac stroke volume (22, 23) and decreases blood pressure (23, 36). Furthermore, systemic administration of alcohol is associated with increases in forearm blood flow (FBF) and coronary blood flow (4, 22, 32). However, studies examining the effect of ethanol on NO-mediated vasodilation in humans have yielded inconsistent results (9, 17). Moreover, such prior observations of the hemodynamic effects of ethanol were made in the setting of oral or intravenous ethanol administration and hence are confounded by interactions of ethanol with the central nervous system (CNS).

The purpose of this study was to test the hypothesis that the vascular actions of ethanol in humans are mediated by endothelium-derived NO. FBF was measured in healthy human subjects during the intra-arterial infusion of endothelium-dependent and -independent vasodilators before and during concomitant intra-arterial administration of ethanol. Thereafter, the local vasomotor effects of ethanol were assessed during inhibition of NO synthase.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Patient population. Healthy subjects were recruited from the greater Boston area. Exclusion criteria included the following: smoking, systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg, serum cholesterol level above the 75th percentile for age and sex, history of vascular disease, diabetes, family history of premature coronary artery disease, or any clinical manifestation of atherosclerosis, such as coronary artery disease, peripheral artery disease, or carotid artery disease. The study protocol was approved by the Partners Joint Human Research Committee, and informed consent was obtained from each subject.

Experimental protocol. Each subject was studied in a 23°C temperature-controlled room in the fasting state. Nonsteroidal anti-inflammatory drugs, alcohol, and caffeine were prohibited for 12 h before study initiation. Under local anesthesia and sterile conditions, a 20-gauge polyethylene catheter was placed in the brachial artery of each subject for determination of blood pressure and for infusion of drugs. The vascular research laboratory was kept quiet, and the lights were dimmed. All subjects rested at least 30 min after catheter placement to establish a stable baseline before data collection. Venous occlusion plethysmography (described below) was employed to measure the FBF response to endothelium-dependent and -independent vasodilators during coadministration of ethanol or vehicle. Methacholine chloride (Provocholine, Roche Labs; Nutley, NJ), a congener of acetylcholine that acts by stimulating NO release from the vascular endothelium, was administered intra-arterially at doses of 0.3, 1.0, 3.0, and 10.0 mcg/min (n = 9). To distinguish abnormalities in endothelial function from those of vascular smooth muscle, sodium nitroprusside (Elkins-Sinn; Cherry Hill, NJ), which acts as a NO donor, was administered intra-arterially at doses of 0.3, 1.0, 3.0, and 10.0 mcg/min (n = 9). To evaluate the direct smooth muscle effects of ethanol independent of NO, the calcium channel antagonist verapamil (American Reagent Laboratory; Shirley, NY) was administered intra-arterially at doses of 10, 30, 100, and 300 mcg/min (n = 9). On each visit, only a single vasodilator was employed to test the mechanism by which ethanol affects FBF. Each vasoactive drug was infused for 5 min at a rate of 0.4 ml/min. A 5% dextrose solution served as the vehicle control for determination of baseline flows.

After the blood flow response to incremental doses of methacholine, nitroprusside, or verapamil was recorded, at least 45–60 min were allowed to pass to ensure reestablishment of basal conditions. Ethanol solution (10% ethanol in 5% dextrose) or vehicle was then infused in the ipsilateral brachial artery. The infusion rate for the ethanol solution was determined using the subject's basal FBF, the concentration of ethanol in the solution, and the desired final blood concentration (200 mg/dl) as computational variables. The total intra-arterial infusion rate (ethanol solution plus dextrose solution) was maintained constant throughout the experimental series for each visit. In all cases, the total amount of ethanol infused during any one visit was <10 gm ethanol, (i.e., less than the amount of ethanol in a single glass of wine). FBF measurements were repeated after ethanol had been infused intra-arterially for 30 min. Thereafter, the dose-response curve to the endothelium-dependent or -independent vasodilator drug was once again assessed, this time during coinfusion of ethanol. Additionally, a time control experiment was conducted (during which the methacholine dose-response curve was measured twice during vehicle infusions, n = 5).

Contribution of NO to verapamil-stimulated vasodilation. Numerous endothelium-independent vasodilators have been shown to elicit NO release (perhaps as a result of enhanced shear stress) (2, 7, 19, 31, 44). As such, to determine whether NO contributes to verapamil-induced vasodilation in humans, FBF was measured during intra-arterial administration of verapamil and during the concomitant administration of vehicle vs. the NO synthase inhibitor NG-nitro-L-arginine (L-NAME; 2 mg/min over 10 min, Clinalfa; Läufelfingen, Switzerland, n = 8).

Contribution of NO to ethanol-augmented vasodilation. Thereafter, we sought to determine whether the vascular responses to ethanol were mediated by the release of NO. We employed verapamil as the vasodilator with which to test this hypothesis for three reasons. First, the classic endothelium-dependent dilator methacholine was not chosen in this subprotocol because NO inhibition is known to significantly attenuate the blood flow response to this pharmacological probe (1). Second, our initial results (from the first series of experiments) suggested that the potentiation by ethanol of vasodilation was greatest during verapamil infusion. Finally, we anticipated that a portion of the blood flow response to verapamil can be attributed to NO, perhaps due to shear stress release of NO after an initially endothelium-independent augmentation of blood flow. After baseline blood flow was reestablished in the eight subjects who participated in the aforementioned verapamil/L-NAME experiment, the FBF response to verapamil was measured again during the concomitant administration of L-NAME (2 mg/min over 10 min) plus ethanol.

Venous occlusion plethysmography. Bilateral FBF was determined by venous occlusion strain-gauge plethysmography using calibrated mercury-in-Silastic strain-gauges (D. E. Hokanson; Bellevue, WA). Each arm was supported above the heart level. Venous occlusion was produced by inflation of a sphygmomanometric cuff on the upper arm. The lowest venous occlusion pressure needed to obtain the maximum rate of increase in forearm circumference was determined at the beginning of each study. Circulation to the hand was prevented by inflating the wrist cuff to suprasystolic pressures during each blood flow determination. FBF measured during each experimental period was composed of at least five different measurements performed at 10-to 15-s intervals. By measuring blood flow in the infused arm, the direct effect of the drug can be measured. By measuring blood flow in the noninfused arm, confirmation can be made that the drug is not causing systemic effects. FBF was derived from the rate of change in forearm volume during venous occlusion and was recorded on a Gould physiological recorder. Measurements were expressed as milliliters per 100 ml of tissue per minute. Brachial arterial pressure was measured via an indwelling arterial cannula. The cannula was attached to a Gould pressure transducer, and the pressure measurements were recorded on a Gould physiological recorder. Forearm vascular resistance (FVR) was calculated as the ratio of mean blood pressure to FBF. To measure heart rate, the electrocardiogram was recorded and continually monitored during the experiments.

Laboratory analyses. Immediately after each ethanol infusion, blood samples were obtained from the ipsi- and contralateral antecubital veins for plasma alcohol measurements. Plasma alcohol was measured by gas chromatography (Hewlett Packard; Palo Alto, CA). Systemic alcohol concentration was also measured at the bedside by means of a portable breath alcohol analyzer (Lifeloc Technologies; Denver, CO).

Statistical analysis. All data are presented as means ± SE. Group comparisons with respect to clinical characteristics were made with unpaired and two-tailed t-tests. FBF dose-response curves for each drug before and during the coadministration of ethanol were analyzed with two-way repeated-measures ANOVA, followed by post hoc two-tailed t-tests adjusted with a Bonferroni correction for multiple comparisons. Statistical significance was accepted at the 95% confidence level (P < 0.05).


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Patient population. Twenty healthy subjects, including 12 men and 8 women (age, 29.5 ± 1.6 yr), participated in the protocols. Most subjects were studied in more than one protocol. The subjects' mean total, LDL, and HDL cholesterol were 161 ± 6, 89 ± 4, and 52 ± 3 mg/dl, respectively.

Blood alcohol concentrations. Mean plasma alcohol concentration after ethanol infusion was 227 ± 30 mg/dl in the veins of the infused forearm. Mean systemic plasma alcohol concentration in the contralateral antecubital veins was only 6 ± 0 mg/dl. The systemic ethanol concentration remained undetectable by breath analysis in all subjects.

Effect of ethanol alone on hemodynamic parameters. Intra-arterial ethanol infusion did not affect either heart rate [from 49 ± 5 to 53 ± 5 beats/min, P = not significant (NS)] or mean arterial pressure (from 76 ± 2 to 77 ± 2 mmHg, P = NS). However, ethanol reduced ipsilateral FBF (from 2.5 ± 0.1 to 1.9 ± 0.1 ml·dl–1·min–1, P < 0.01; Fig. 1) and increased FVR (from 36 ± 3 to 47 ± 4 mmHg·ml–1·dl·min, P < 0.05). In contrast, ethanol infusion did not affect contralateral FBF (from 1.6 ± 0.1 to 1.7 ± 0.2 ml·dl–1·min–1, P = NS) or FVR (from 49 ± 4 to 52 ± 6 mmHg·ml–1·dl·min, P = NS).



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 1. Effect of ethanol (EtOH) on resting forearm blood flow (FBF). The effect of EtOH on FBF was determined during the infusion of vehicle vs. ethanol. EtOH infusion was associated with a reduction in resting FBF in 23 of 27 subjects (P < 0.01). , Individual data point; {blacksquare}, mean data.

 
Effect of ethanol on endothelium-dependent and -independent vasodilation. Ethanol infusion was associated with a significant upward shift in the ipsilateral FBF dose-response curves for each of the endothelium-dependent and -independent vasodilators (P < 0.05 by ANOVA for methacholine, nitroprusside, and verapamil; Fig. 2, A–C). During the highest dose of methacholine, FBF was 24.4 ± 1.9 ml·dl–1·min–1 when vehicle was coinfused and 28.6 ± 1.4 ml·dl–1·min–1 when ethanol was coinfused (P < 0.01). Similarly, during the highest dose of nitroprusside, FBF was 18.5 ± 1.4 ml·dl–1·min–1 when vehicle was coinfused and 21.4 ± 2.3 ml·dl–1·min–1 when ethanol was coinfused (P < 0.05). Likewise, during the highest dose of verapamil, FBF was 20.0 ± 2.6 ml·dl–1·min–1 when vehicle was coinfused and 25.0 ± 2.6 ml·dl–1·min–1 when ethanol was coinfused (P < 0.05). This effect was consistent; ethanol augmented FBF at the highest dose of vasodilator in 22 of 27 subjects. In congruence with these findings, FVR dose-response curves were reduced by a greater extent during ethanol infusion for each of the endothelium-dependent and -independent vasodilators (P < 0.05 by ANOVA for methacholine, nitroprusside, and verapamil). In contrast to those findings, in the time control experiment, (during which the FBF response to methacholine was measured twice during vehicle infusions), there was a nonsignificant reduction in FBF during the second series of measurements (P = NS; Fig. 2D). Furthermore, there were no significant changes in contralateral FBF or FVR during any of the intra-arterial infusions.



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2. A: effect of EtOH on endothelium-dependent vasodilation. The effect of EtOH on FBF was determined in response to the endothelium-dependent vasodilator methacholine. Ethanol infusion was associated with a significant upward shift in the FBF dose-response curve for methacholine (P < 0.05 by ANOVA). B: effect of EtOH on endothelium-independent vasodilation. The effect of EtOH on FBF was determined in response to the endothelium-independent nitric oxide (NO) donor nitroprusside. Ethanol infusion was associated with a significant upward shift in the FBF dose-response curve for nitroprusside (P < 0.05 by ANOVA). C: effect of EtOH on NO-independent vasodilation. The effect of EtOH on FBF was determined in response to the endothelium-independent vasodilator verapamil. EtOH infusion was associated with a significant upward shift in the FBF dose-response curve for verapamil (P < 0.05 by ANOVA). D: time and vehicle control. To assess the effect of time on FBF, the dose-response curve to methacholine was determined twice in response to vehicle. There was a nonsignificant reduction in FBF during the second series of measurements (P = not significant by ANOVA).

 
Effect of NO synthase inhibition. The nitric oxide synthase inhibitor L-NAME did not affect resting heart rate (58 ± 8 vs. 58 ± 10 beats/min, P = NS) or mean arterial pressure (76 ± 11 vs. 75 ± 10 mmHg, P = NS). However, L-NAME was associated with an approximate 19% reduction in basal ipsilateral FBF (2.6 ± 0.4 to 2.1 ± 0.4 ml·dl–1·min–1, P < 0.01; Fig. 3A). This effect was consistent; L-NAME reduced FBF at rest in eight of eight subjects. This was paralleled by a significant increase in FVR (30.4 ± 6.9 vs. 38.2 ± 10.1 mmHg·ml–1·dl·min, P < 0.05). Furthermore, L-NAME infusion significantly attenuated the FBF dose-response curves to verapamil (P < 0.05 by ANOVA; Fig. 3A). The effect of L-NAME on verapamil-stimulated vasodilation was consistent; FBF at the highest dose of verapamil was reduced in eight of eight subjects.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3. A: contribution of NO release to verapamil-stimulated vasodilation. The FBF response to verapamil was determined in the presence of the NO synthase antagonist NG-nitro-L-arginine (L-NAME) vs. vehicle. L-NAME infusion was associated with a significant reduction in resting FBF. Furthermore, L-NAME infusion was associated with a significant downward shift in the FBF dose-response curve for verapamil (P < 0.05 by ANOVA), thereby demonstrating a role for NO in verapamil-stimulated vasodilation. B: NO synthase inhibition and EtOH-augmented vasodilation. During the coinfusion of verapamil and L-NAME, FBF was measured in the presence of EtOH vs. vehicle. Despite concomitant inhibition of NO synthesis, EtOH infusion resulted in a significant upward shift in the FBF dose-response curve (P < 0.05 by ANOVA). Base, baseline.

 
During the coinfusion of L-NAME, ethanol did not further reduce resting FBF (2.3 ± 0.2 to 2.1 ± 0.3 ml·dl–1·min–1, P = NS). Moreover, L-NAME did not blunt the ability of ethanol to upwardly shift the FBF dose-response relationship to verapamil (P < 0.05 by ANOVA; Fig. 3B). Despite the coinfusion of L-NAME, FBF increased in seven of eight subjects during ethanol and high-dose verapamil infusion.


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The important new findings of this study are that 1) intra-arterial ethanol infusion causes limb vasoconstriction at rest, and 2) ethanol enhances the FBF response to endothelium-dependent and -independent vasodilators via a mechanism that does not involve NO.

Effect of ethanol on NO bioavailability. This study tested the hypothesis that ethanol directly affects vasomotor function by acutely enhancing NO bioavailability. Such a finding would have highlighted a potential mechanism by which ethanol reduces cardiovascular mortality, because an increase in NO might lead to a reduction in the manifestations of atherosclerosis (via a decrease in vasoconstriction, leukocyte recruitment, platelet aggregation, and vascular smooth muscle proliferation). Indeed, animal and cellular studies have suggested that ethanol may increase NO bioavailability. Vascular strips taken from alcohol-fed rats relax more readily in response to acetylcholine (a stimulant for NO release) than vascular strips taken from control animals (18), and endothelial cells incubated with alcohol express more NO synthase mRNA (46) and greater l-citrulline conversion (a marker for NO production) (6).

Prior human studies that assessed the effect of ethanol on NO bioavailability have yielded conflicting results. The ingestion of red wine has been associated in an increase in serum NO (measured by fluorescent indicator) and improved flow-mediated vasodilation in some studies, whereas other studies found no improvement in NO-mediated vasodilation after red wine ingestion (9, 30). However, in each of those studies, measurements were made in response to systemic administration of ethanol. Ethanol is known to increase sympathetic activation via effects on the CNS (21, 22, 33, 45), thereby confounding the observations.

Thus, in the present study, we sought to examine the direct effect of ethanol on human vasomotor function. To accomplish this, ethanol was infused locally, via arterial catheter, into the vascular bed being studied, dosed to achieve a forearm concentration of 227 mg/dl, which is equivalent to that achieved after drinking four to six glasses of wine over 1 h. It is notable that the mean local blood alcohol concentration attained in this study is not frequently encountered during casual ethanol consumption (for comparison, the typical legal blood alcohol limit for driving an automobile in the United States is 100 mg/dl). Nonetheless, in the present study, systemic alcohol concentrations remained negligible. Therefore, the data reflect the direct effects of ethanol and are not confounded by the effects of ethanol on the CNS.

Effect of ethanol on resting blood flow. We found that ethanol acutely and directly reduces resting FBF and increases FVR in humans. This observation may be relevant to the noted association between chronic, heavy ethanol intake and hypertension (24, 25–27, 29). Prior observations suggested that alcohol induces pressor effects by sympathetic activation that appears to be centrally mediated (33).The vasoconstrictor effect observed in the present study is unlikely to result from centrally mediated changes in sympathetic tone, because systemic alcohol concentrations remained negligible during the course of this study and because contralateral FBF remained unchanged. The mechanism of the direct, acute vasoconstrictor effect of ethanol remains to be elucidated.

Ethanol augments vasodilation. Despite this initial vasoconstriction, ethanol increased the dilator response to methacholine, nitroprusside, and verapamil. This potentiating effect of ethanol was most apparent at the higher doses of vasodilators infused. In contrast, repeat infusion of vehicle (as a time control) did not change the vasodilator responses (a trend toward reduced vasodilation was instead seen).

The observation that ethanol augments both "endothelium-dependent" and "endothelium-independent" vasodilation does not, on its own, exclude the possibility that the mechanism of the effect of ethanol involves an endothelial release of NO. Indeed, several vasodilator drugs that are traditionally classified as endothelium independent have been shown to elicit NO release (2, 7, 19, 31, 44). In such cases, the initial endothelium-independent stimulus causes an increase in flow, which can potentially lead to additional increases in flow as a result of shear-stress-mediated NO release.

NO contributes to the dilator effect of verapamil. To test the hypothesis that NO release contributes to the vasodilator response of the classically endothelium-independent vasodilator verapamil, FBF was measured during intra-arterial administration of verapamil and during the concomitant administration of vehicle vs. L-NAME. During this series of experiments, we made the novel observation that NO synthase inhibition attenuates verapamil-induced vasodilation (Fig. 3A). This observation supports the hypothesis that NO release plays a role in the vasodilatory effect of verpamil in vivo. It follows, then, that although verapamil initially causes relaxation on vascular smooth muscle by inhibiting calcium channels, additional vasodilation may occur in vivo as a result of NO release (possibly resulting from shear-stress-mediated NO release).

Augmentation of vasodilation by ethanol occurs independently of NO. However, the same concentration of L-NAME did not prevent the ability of ethanol to augment vasodilation (Fig. 3B). Taken together, these data suggest that ethanol directly augments both endothelium-dependent and -independent vasodilation via a mechanism that is independent of NO. Moreover, the observation that NO does not play a role in the local vasoactive effects of ethanol does not directly conflict with the prior observations showing that alcoholic beverages enhance NO bioavailability. Indeed, prior studies suggest that it is the nonalcohol components in wine that are responsible for the NO release (12, 40).

Potential mechanisms. Although these data demonstrate that NO does not play a significant role in the acute, direct effect of ethanol on vascular tone, the precise mechanisms by which ethanol altered vascular function in humans remains unexplained. It is plausible that the vascular effects of ethanol may result from its unique biophysical properties: the compact bipolar structure of ethanol allows it to readily intercalate within the lipid bilayer (3). As such, it may alter the actions of cell membrane channels (3), an ability that is thought to be responsible for some of the anesthetic properties of ethanol (3, 38, 39, 42). Therefore, an effect on membrane ion channels is an attractive potential mechanism that may explain the vasoactive effects of ethanol.

Study limitations. Caution should be exercised when extrapolating the direct, acute effects of pure alcohol to the effects of chronic, moderate consumption of alcoholic beverages. First, the vascular effect of pure ethanol may differ form the effect of alcoholic beverages, because some alcoholic beverages contain compounds that may have beneficial vascular actions that are independent of ethanol (12). Second, because by design systemic ethanol levels in this study were negligible, the findings of this study can not account for potentially important indirect effects of ethanol or of by-products of ethanol metabolism. Third, the study examined only the acute effects of ethanol and may not reflect the chronic vasomotor effects of ethanol. Fourth, the lack of a significant fall in FBF after ethanol is added to L-NAME should be interpreted with caution, because the study was neither designed nor powered to examine the role of NO in ethanol-mediated vasoconstriction at rest. Finally, the present study examined the acute, direct effects of ethanol on healthy subjects. As such, some of the observed findings (especially the magnitude of FBF change) may differ in a population with established atherosclerosis.

Clinical implications. The divergent direct vascular effects of ethanol reported in this study (resting vasoconstriction and potentiation of vasodilation) may, at first glance, seem counterintuitive. However, they coincide with two well-described clinical effects of alcohol consumption: hypertension (24, 25–27, 29) and potentiation of syncope (11). Indeed, a biphasic response to ethanol ingestion has been previously described (36).

In conclusion, the results of this investigation indicate that in healthy humans, ethanol acutely 1) induces vasoconstriction at rest, and 2) augments endothelium-dependent and -independent vasodilation via a mechanism that does not involve NO. Further studies are needed to determine the mechanisms underlying the vascular actions of this commonly used compound.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported in part by National Heart, Lung, and Blood Institute Grants HL-10107 (to A. Tawakol) and HL-48743 (to M. A. Creager) and by a grant from the Cardiofellows Foundation (to A. Tawakol). T. Omland is a recipient of the Fulbright Scholarship Award. M. A. Creager is the Simon C. Fireman Scholar in Cardiovascular Medicine at Brigham and Women's Hospital.


   FOOTNOTES
 

Address for reprint requests and other correspondence: M. A. Creager, Cardiovascular Div., Brigham and Women's Hospital, Boston, MA 02115 (E-mail: mcreager{at}partners.org).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pfaffendorf M, and van Zwieten PA. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Blood Press 5: 333–341, 1996.[Medline]
  2. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, and Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104: 2305–2310, 2001.[Abstract/Free Full Text]
  3. Chin JH and Goldstein DB. Drug tolerance in biomembranes: a spin label study of the effects of ethanol. Science 196: 684–685, 1977.[Abstract/Free Full Text]
  4. Cigarroa RG, Lange RA, Popma JJ, Yurow G, Sills MN, Firth BG, and Hillis LD. Ethanol-induced coronary vasodilation in patients with and without coronary artery disease. Am Heart J 119: 254–259, 1990.[CrossRef][Web of Science][Medline]
  5. Corder R. Endothelin-1 synthesis reduced by red wine. Nature 414: 863–864, 2001.[CrossRef][Medline]
  6. Davda RK, Chandler LJ, Crews FT, and Guzman NJ. Ethanol enhances the endothelial nitric oxide synthase response to agonists. Hypertension 21: 939–943, 1993.[Abstract/Free Full Text]
  7. Dawes M, Chowienczyk PJ, and Ritter JM. Effects of inhibition of the l-arginine/nitric oxide pathway on vasodilation caused by {beta}-adrenergic agonists in human forearm. Circulation 95: 2293–2297, 1997.[Abstract/Free Full Text]
  8. Diebolt M, Bucher B, and Andriantsitohaina R. Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension 38: 159–165, 2001.[Abstract/Free Full Text]
  9. Djousse L, Ellison RC, McLennan CE, Cupples LA, Lipinska I, Tofler GH, Gokce N, and Vita JA. Acute effects of a high-fat meal with and without red wine on endothelial function in healthy subjects. Am J Cardiol 84: 660–664, 1999.[CrossRef][Web of Science][Medline]
  10. Doll R, Peto R, Hall E, Wheatley K, and Gray R. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ 309: 911–918, 1994.[Abstract/Free Full Text]
  11. Fisher CM. Syncope of obscure nature. Can J Neurol Sci 6: 7–20, 1979.[Web of Science][Medline]
  12. Fitzpatrick DF, Hirschfield SL, and Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol Heart Circ Physiol 265: H774–H778, 1993.[Abstract/Free Full Text]
  13. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, and Hennekens CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 329: 1829–1834, 1993.[Abstract/Free Full Text]
  14. Goldberg RJ, Burchfiel CM, Reed DM, Wergowske G, and Chiu D. A prospective study of the health effects of alcohol consumption in middle-aged and elderly men. The Honolulu Heart Program. Circulation 89: 651–659, 1994.[Abstract/Free Full Text]
  15. Greenberg SS, Xie J, Wang Y, Kolls J, Shellito J, Nelson S, and Summer WR. Ethanol relaxes pulmonary artery by release of prostaglandin and nitric oxide. Alcohol 10: 21–29, 1993.[CrossRef][Web of Science][Medline]
  16. Handa K, Sasaki J, Saku K, Kono S, and Arakawa K. Alcohol consumption, serum lipids and severity of angiographically determined coronary artery disease. Am J Cardiol 65: 287–289, 1990.[CrossRef][Web of Science][Medline]
  17. Hashimoto M, Kim S, Eto M, Iijima K, Ako J, Yoshizumi M, Akishita M, Kondo K, Itakura H, Hosoda K, Toba K, and Ouchi Y. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am J Cardiol 88: 1457–1460, 2001.[CrossRef][Web of Science][Medline]
  18. Hatake K, Wakabayashi I, Kakishita E, Taniguchi T, Ouchi H, and Hishida S. Development of tolerance to inhibitory effect of ethanol on endothelium-dependent vascular relaxation in ethanol-fed rats. Alcohol Clin Exp Res 15: 112–115, 1991.[CrossRef][Web of Science][Medline]
  19. Hein TW and Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and KATP channels. Circ Res 85: 634–642, 1999.[Abstract/Free Full Text]
  20. Hendriks HF, Veenstra J, Velthuis-te Wierik EJ, Schaafsma G, and Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. BMJ 308: 1003–1006, 1994.[Abstract/Free Full Text]
  21. Johnson RH, Eisenhofer G, and Lambie DG. The effects of acute and chronic ingestion of ethanol on the autonomic nervous system. Drug Alcohol Depend 18: 319–328, 1986.[CrossRef][Web of Science][Medline]
  22. Kelbaek H, Floistrup S, Gjorup T, Christensen NJ, Hartling OJ, and Godtfredsen J. Central and peripheral haemodynamic changes after alcohol ingestion. Alcohol Alcohol 23: 211–216, 1988.[Abstract/Free Full Text]
  23. Kelbaek H, Heslet L, Skagen K, Christensen NJ, Godtfredsen J, and Munck O. Hemodynamic effects of alcohol at rest and during upright exercise in coronary artery disease. Am J Cardiol 61: 61–64, 1988.[CrossRef][Web of Science][Medline]
  24. Klag MJ, He J, Whelton PK, Chen JY, Qian MC, and He GQ. Alcohol use and blood pressure in an unacculturated society. Hypertension 22: 365–370, 1993.[Abstract/Free Full Text]
  25. Klatsky AL, Friedman GD, and Armstrong MA. The relationships between alcoholic beverage use and other traits to blood pressure: a new Kaiser Permanente study. Circulation 73: 628–636, 1986.[Abstract/Free Full Text]
  26. Klatsky AL, Friedman GD, and Siegelaub AB. Alcohol and mortality. A ten-year Kaiser-Permanente experience. Ann Intern Med 95: 139–145, 1981.[Abstract/Free Full Text]
  27. Klatsky AL, Friedman GD, and Siegelaub AB. Alcohol use and cardiovascular disease: the Kaiser-Permanente experience. Circulation 64: III-32–III-41, 1981.
  28. Klatsky AL, Friedman GD, Siegelaub AB, and Gerard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med 296: 1194–1200, 1977.[Abstract]
  29. MacMahon S. Alcohol consumption and hypertension. Hypertension 9: 111–121, 1987.[Abstract/Free Full Text]
  30. Matsuo S, Nakamura Y, Takahashi M, Ouchi Y, Hosoda K, Nozawa M, and Kinoshita M. Effect of red wine and ethanol on production of nitric oxide in healthy subjects. Am J Cardiol 87: 1029–1031, 2001.[CrossRef][Web of Science][Medline]
  31. Parent R, Pare R, and Lavallee M. Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs. Am J Physiol Heart Circ Physiol 262: H10–H16, 1992.[Abstract/Free Full Text]
  32. Pirwitz MJ, Lange RA, Willard JE, Landau C, Glamann DB, Foerster EH, Todd E, and Hillis LD. Effects of intravenous ethanol on diameter of epicardial coronary arteries. Am J Cardiol 75: 77–79, 1995.[CrossRef][Web of Science][Medline]
  33. Randin D, Vollenweider P, Tappy L, Jequier E, Nicod P, and Scherrer U. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 332: 1733–1737, 1995.[Abstract/Free Full Text]
  34. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, and Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 272: 929–933, 1994.[Abstract/Free Full Text]
  35. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, and Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 338: 464–468, 1991.[CrossRef][Web of Science][Medline]
  36. Rosito GA, Fuchs FD, and Duncan BB. Dose-dependent biphasic effect of ethanol on 24-h blood pressure in normotensive subjects. Am J Hypertens 12: 236–240, 1999.[CrossRef][Web of Science][Medline]
  37. Rubin R and Rand ML. Alcohol and platelet function. Alcohol Clin Exp Res 18: 105–110, 1994.[CrossRef][Web of Science][Medline]
  38. Slater SJ, Cox KJ, Lombardi JV, Ho C, Kelly MB, Rubin E, and Stubbs CD. Inhibition of protein kinase C by alcohols and anaesthetics. Nature 364: 82–84, 1993.[CrossRef][Medline]
  39. Slater SJ, Kelly MB, Larkin JD, Ho C, Mazurek A, Taddeo FJ, Yeager MD, and Stubbs CD. Interaction of alcohols and anesthetics with protein kinase Calpha. J Biol Chem 272: 6167–6173, 1997.[Abstract/Free Full Text]
  40. Soares De Moura R, Costa Viana FS, Souza MA, Kovary K, Guedes DC, Oliveira EP, Rubenich LM, Carvalho LC, Oliveira RM, Tano T, and Gusmao Correia ML. Antihypertensive, vasodilator and antioxidant effects of a vinifera grape skin extract. J Pharm Pharmacol 54: 1515–1520, 2002.[CrossRef][Web of Science][Medline]
  41. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, and Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 319: 267–273, 1988.[Abstract]
  42. Stubbs CD and Slater SJ. Ethanol and protein kinase C. Alcohol Clin Exp Res 23: 1552–1560, 1999.[CrossRef][Web of Science][Medline]
  43. Suh I, Shaten BJ, Cutler JA, and Kuller LH. Alcohol use and mortality from coronary heart disease: the role of high-density lipoprotein cholesterol. The Multiple Risk Factor Intervention Trial Research Group. Ann Intern Med 116: 881–887, 1992.[Abstract/Free Full Text]
  44. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, Cooke JP, Loscalzo J, Fischman AJ, Creager MA, and Gewirtz H. Homocysteine impairs coronary microvascular dilator function in humans. J Am Coll Cardiol 40: 1051–1058, 2002.[Abstract/Free Full Text]
  45. Van de Borne P, Mark AL, Montano N, Mion D, and Somers VK. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension 29: 1278–1283, 1997.[Abstract/Free Full Text]
  46. Venkov CD, Myers PR, Tanner MA, Su M, and Vaughan DE. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb Haemost 81: 638–642, 1999.[Web of Science][Medline]



This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
G. Dumont, C. Kramers, F. Sweep, J. Willemsen, D. Touw, R. Schoemaker, J. van Gerven, J. Buitelaar, and R. Verkes
Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology
J Psychopharmacol, February 1, 2010; 24(2): 165 - 174.
[Abstract] [PDF]

Home page
 Alcohol AlcoholHome page
X.-C. Ru, L.-B. Qian, Q. Gao, Y.-F. Li, I. C. Bruce, and Q. Xia
Alcohol Induces Relaxation of Rat Thoracic Aorta and Mesenteric Arterial Bed
Alcohol Alcohol., September 1, 2008; 43(5): 537 - 543.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. Sidi, B. Naik, J. D. Muehlschlegel, D. S. Kirby, and E. B. Lobato
Ethanol-induced acute pulmonary hypertension and right ventricular dysfunction in pigs
Br. J. Anaesth., April 1, 2008; 100(4): 568 - 569.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
A. Nohria, M. Gerhard-Herman, M. A. Creager, S. Hurley, D. Mitra, and P. Ganz
Role of nitric oxide in the regulation of digital pulse volume amplitude in humans
J Appl Physiol, August 1, 2006; 101(2): 545 - 548.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/6/H2468    most recent
01207.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tawakol, A.
Right arrow Articles by Creager, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tawakol, A.
Right arrow Articles by Creager, M. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.